The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ORGANIZATION
ORGANIZATION
- PhRMA Chair Repeats Call for Keeping Price Maintenance Premium to Secure Market Predictability
April 13, 2017
- JGA Fires Back at Criticism on “Excessive” and “Expensive” Generics, Says No. of Makers Not So Many
April 11, 2017
- Asian Industry Groups Promote Collaboration to Discover Drugs from Natural Resources by Leveraging Asia’s Diverse Ecosystems
April 10, 2017
- JPMA to Support Japanese Drug Makers’ Overseas Expansion through Public-Private Cooperation
April 10, 2017
- Tap Tax Cuts and AMED Subsidies, not Price Premium, to Fuel Innovation: JMA Chief
April 7, 2017
- 26 Japan CRO Association Members Enjoy 12.7% Sales Jump in 2016
April 6, 2017
- Kampo Study Group Submits Proposal to LDP Lawmakers, Cites “Concerns About Stable Supply at Current NHI Prices”
April 6, 2017
- 3 Groups Lay Out Guidelines on Inter-Pharmacy Drug Transactions after Harvoni Flub
April 4, 2017
- GHIT Fund to Invest a Total of US$23 Million in 11 Projects
April 3, 2017
- Generic Use Rate at 66.4% in October-December: JGA
March 31, 2017
- Wholesalers to Address Product Return Issue after Fake Harvoni Case: JPWA Chair
March 28, 2017
- Vaccine Association to Standardize Presentation of Expiration Dates above Inspection Dates on Outer Packaging
March 27, 2017
- FPMAJ to Keep Ex-Bureaucrat Kimura as Director General to Secure Lobbying Continuity
March 24, 2017
- JPMA Reprimands Celgene over Side Effect Reporting Violation
March 24, 2017
- Use “Specified Clinical Research” Data for Drug Approval: Regulatory Science Society
March 23, 2017
- Study Group Presents Proposal for Future Vision for Kampo Medicines
March 21, 2017
- Industry Wants Real-World Data to Serve as Grounds for Drug Pricing: JPMA Head
March 7, 2017
- EFPIA Japan to Compile Policy Proposal on Pricing Reform by Early April: New Chair
March 1, 2017
- 3 Groups to Draw Up Guidelines on Inter-Pharmacy Drug Transactions by March-End
February 27, 2017
- US Exclusion from Foreign Price Adjustment Should Be Carefully Considered: PhRMA Japan Chief
February 2, 2017
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…